MedTrace Logo

Universal CAR-T Cell Therapy for NHL

NCT07248163 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-11-25

No results posted yet for this study

Summary

This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.

Conditions

  • Non-hodgkin Lymphoma,B Cell

Interventions

DRUG

BRL-301

The administered dose is 5×10\^6/kg

Sponsors & Collaborators

  • Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

    collaborator UNKNOWN

  • Bioray Laboratories

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-11
Primary Completion
2027-08-15
Completion
2028-03-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07248163 on ClinicalTrials.gov